research article
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis
Abstract
Blood biomarkers; Multiple sclerosis diagnosisBiomarcadores sanguíneos; Diagnóstico; Esclerosis múltipleBiomarcadors sanguinis; Diagnòstic; Esclerosi múltipleBackground and Objectives Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), chitinase-3-like 1 (sCHI3L1), and the immune responses to the Epstein-Barr virus–encoded nuclear antigen 1 to current MS diagnostic criteria. Methods In this multicentric study, we selected patients from 2 prospective cohorts presenting a clinically isolated syndrome (CIS). Patients were classified as (1) not presenting dissemination in space (DIS) nor dissemination in time (DIT) (noDIS and noDIT); (2) presenting DIS without DIT (DIS and noDIT); and (3) presenting both (DIS and DIT), which were used as a reference. sNfL, sGFAP, and sCHI3L1 levels were measured with single-molecule array immunoassays and EBNA1-specific IgG levels with ELISA. Biomarker levels were compared between groups using linear regression models. Receiver operating characteristic curve analyses and Youden Index were used to determine cutoff values associated with MS diagnosis during follow-up. Results We included 181 patients (66.3% females, mean [SD] age of 35.0 [9.7] years). At baseline, 25 (13.8%) were classified as noDIS and noDIT, 62 (34.3%) as DIS and noDIT, and 94 (51.9%) as DIS and DIT. Only sNfL Z-scores discriminated between groups (DIS and DIT vs DIS and noDIT [p = 0.002], DIS and DIT vs noDIS and noDIT [p < 0.001], and DIS and noDIT vs noDIS and noDIT [p = 0.026]). In noDIS and noDIT patients (median interquartile range [IQR] follow-up of 8.1 [5.0–11.7] years), high sNfL Z-scores best predicted MS diagnosis (specificity [SP] and 95% CI of 93.3% [68.1–99.8] and positive predictive value [PPV] of 87.5% [47.3–99.7]). Among DIS and noDIT patients (median [IQR] follow-up of 6.8 [4.0–9.1] years), high sNfL Z-scores best predicted MS diagnosis (SP of 80% [28.4–99.5] and PPV of 97.3% [85.8–99.9]) without considering oligoclonal band (OB) status. In the subset of patients of this group with negative OBs, a combination of high sNfL Z-scores and sGFAP levels predicted MS diagnosis (SP of 100% [39.8–100] and PPV of 100% [54.1–100]). Discussion These results suggest that sNfL and sGFAP may be incorporated in particular scenarios to diagnose MS in patients with CIS not fulfilling current diagnostic criteria- info:eu-repo/semantics/article
- info:eu-repo/semantics/publishedVersion
- Esclerosi múltiple - Diagnòstic
- Marcadors bioquímics
- Biopolímers
- DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis
- Other subheadings::Other subheadings::/diagnosis
- CHEMICALS AND DRUGS::Biological Factors::Biomarkers
- Other subheadings::Other subheadings::Other subheadings::/blood
- CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Neurofilament Proteins
- CHEMICALS AND DRUGS::Macromolecular Substances::Polymers::Biopolymers::Intermediate Filament Proteins::Glial Fibrillary Acidic Protein
- ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple
- Otros calificadores::Otros calificadores::/diagnóstico
- COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
- Otros calificadores::Otros calificadores::Otros calificadores::/sangre
- COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteínas de neurofilamentos
- COMPUESTOS QUÍMICOS Y DROGAS::sustancias macromoleculares::polímeros::biopolímeros::proteínas de filamentos intermedios::proteína ácida fibrilar de la glía